Abstract

Real-world studies on the use of biologics in psoriasis (Pso) are increasing, but still scarce. Next, interleukin-17 inhibitors (IL-17i) trough concentrations (Ct) seem promising for clinical decision making, however its value in daily practice has yet to be proven. Objectives were to report on IL-17i effectiveness, treatment modifications, and Ct use in our clinic. Data was collected from IL-17i treated Pso patients followed up in the PsoPlus clinic at the Dermatology department, Ghent University Hospital, Belgium.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.